In the claims:

Please amend the claims as follows:

1. (Currently Amended) A cyclosporin represented by the formula

A---B---Sar-MeLeu-Val-MeLeu-Ala---U---MeLeu-MeLeu-MeVal
1 2 8 (1)

wherein
A is



X is absent, -C1-C6 alkyl-, or –C3-C6 cycloalkyl-;

Y is selected from the group consisting of:

(i) C(O)-O-R1, where R1 is ~~hydrogen,~~ C1-C6 alkyl, which is substituted with halogen, heterocyclic, aryl, C1-C6-alkoxy, C1-C6 alkylthio, halogen-substituted C1-C6 alkoxy,or halogen-substituted C1-C6 alkylthio;

(ii) C(O)-S-R1, where R1 is as previously defined;

(iii) C(O)-OCH2-OC(O)R2, where R2 is C1-C6 alkyl, optionally substituted with halogen, C1-C6 alkoxy, C1-C6 alkylthio, heterocyclic or aryl;

(iv) C(S)-O-R1, where R1 is as previously defined; and

(v) C(S)-S-R1, where R1 is as previously defined;

B is –αAbu-, -Val-, -Thr- or –Nva-; and

U is –(D)Ala-, -(D)Ser-, –[O-(2-hydroxyethyl)(D)Ser]-, -[O-acyl(D)Ser]- or -[O-(2-acyloxyethyl)(D)Ser]-,

or a pharmaceutically acceptable salt thereof.

2. (Previously Amended) A cyclosporin according to claim 1 wherein B is –αAbu-, and U is –(D)Ala-.

3. (Currently Amended) A cyclosporin according to claim 1, wherein B is –αAbu-, U is –(D)Ala-,

X is absent, and Y is selected from a group consisting of:

C(O)-O-R1 where R1 is ~~hydrogen~~, C1-C6 alkyl, which is substituted with halogen, heterocyclic, aryl, C1-C6-alkoxy, C1-C6-alkylthio, halogen- substituted C1-C6 alkoxy,or halogen-substituted C1-C6 alkylthio;

C(O)-S-R1 where R1 is as previously defined;

C(O)-OCH_2-OC(O)R2 where R2 is C1-C6 alkyl, optionally substituted with halogen, C1-C6-alkoxy, C1-C6-alkylthio, heterocyclic or aryl.

4. (Previously Amended) A cyclosporin according to claim 1 which is selected from the group consisting of:

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = $COOCH_2Ph$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = $COOCH_2F$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = $COOCHF_2$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = $COOCF_3$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = $COOCH_2CF_3$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = $COOCH_2Cl$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = $COOCH_2OCH_3$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = $COOCH_2OCH_2CH_2OCH_3$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = $C(O)SCH_2Ph$;

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is $–CH_2CH_2CH_2-$, Y = $COOCH_3$; and

Compound of Formula (I) wherein B = –αAbu-, U = –(D)Ala-, X is absent, Y = COOFmoc.

Please cancel claims 5-7.

8. (Original) A pharmaceutical composition for topical administration comprising a cyclosporin compound of claim 1 together with a pharmaceutically acceptable diluent or carrier therefor.

9. (Original) A method for treating inflammatory or obstructive airways disease in a subject in need of said treatment, which comprises topically administering to said subject a therapeutically effective amount of a cyclosporin compound of claim 1.

10. (Original) The method of claim 9 wherein said step of topically administering is by inhalation.

11. (Currently Amended) The method of claim 9, wherein said airways disease is asthma, allergic rhinitis, bronchitis, ~~COPD~~chronic obstructive pulmonary disease, chronic bronchitis or cystic fibrosis.